Comparing single-agent with doublet chemotherapy in first-line treatment of advanced non-small cell lung cancer with performance status 2: A meta-analysis

Asia-Pacific Journal of Clinical Oncology

Volumn 11, Issue 3, 2015, Pages 253-261

  Luo, Long ^a,b   Hu, Qian ^a   Jiang, Jun Xia ^a   Yang, Xing ^a   Dinglin, Xiao Xiao ^a   Lin, Xiao ^a   Yao, He Rui ^a  

^a SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b Yiyang Central Hospital   (China)

Author keywords

Doublet; Meta analysis; Non small cell lung cancer; Performance status 2; Single agent

Indexed keywords

CARBOPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; ANTINEOPLASTIC AGENT;

ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DYSPNEA; FATIGUE; HEMATOLOGIC DISEASE; HUMAN; META ANALYSIS; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RISK FACTOR; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; LUNG NEOPLASMS; MALE; MORTALITY; PATHOLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; SURVIVAL RATE;

EID: 84939256054     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/ajco.12359     Document Type: Article

References (17)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83: 584-594.
3. Ettinger DS, Akerley W, Borghaei H etal. Non-small cell lung cancer. J Natl Compr Canc Netw 2012; 10: 1236-1271.
4. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996; 32A: 1135-1141.
5. Ruckdeschel JC, Finkelstein DM, Ettinger DS etal. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986; 4: 14-22.
6. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest 2002; 122: 1037-1057.
7. Azzoli CG, Temin S, Aliff T etal. Focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2011; 29: 3825-3831.
8. Jadad AR, Moore RA, Carroll D etal. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
9. Perrone F, Di Maio M, Gallo C, Gridelli C. Outcome of patients with a of 2 in the Multicenter Italian Lung Cancer in the Elderly Study (MILES). J Clin Oncol 2004; 22: 5018-5020. author reply 20-1.
10. Lilenbaum RC, Herndon JE 2nd, List MA etal. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol 2005; 23: 190-196.
11. Kosmidis PA, Dimopoulos MA, Syrigos K etal. Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol 2007; 2: 135-140.
12. Hainsworth JD, Spigel DR, Farley C etal. Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized phase 3 trial of the Minnie Pearl Cancer Research Network. Cancer 2007; 110: 2027-2034.
13. Reynolds C, Obasaju C, Schell MJ etal. Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 2009; 27: 5808-5815.
14. Zukin M, Barrios CH, Pereira JR etal. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 2013; 31: 2849-2853.
15. Gridelli C. Does chemotherapy have a role as palliative therapy for unfit or elderly patients with non-small-cell lung cancer? Lung Cancer 2002; 38 (Suppl 2): S45-50.
16. Sweeney CJ, Zhu J, Sandler AB etal. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a phase II trial in patients with metastatic nonsmall cell lung carcinoma. Cancer 2001; 92: 2639-2647.
17. Morabito A, Gebbia V, Di Maio M etal. Randomized phase III trial of gemcitabine and cisplatin versus gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: the CAPPA-2 study. Lung Cancer 2013; 81: 77-83.